Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.20 Consensus Target Price from Brokerages

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $36.20.

A number of analysts recently issued reports on SNDX shares. The Goldman Sachs Group raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. Stifel Nicolaus boosted their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, October 14th. HC Wainwright reiterated a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. Finally, StockNews.com cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd.

View Our Latest Stock Analysis on Syndax Pharmaceuticals

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX opened at $14.25 on Wednesday. The firm has a market capitalization of $1.22 billion, a P/E ratio of -3.93 and a beta of 0.89. Syndax Pharmaceuticals has a 12 month low of $12.06 and a 12 month high of $25.34. The company’s fifty day moving average price is $14.39 and its 200 day moving average price is $18.04.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same period last year, the company posted ($0.73) earnings per share. On average, sell-side analysts anticipate that Syndax Pharmaceuticals will post -3.71 EPS for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. R Squared Ltd bought a new position in Syndax Pharmaceuticals during the fourth quarter worth $26,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Syndax Pharmaceuticals in the second quarter worth $27,000. Values First Advisors Inc. bought a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $30,000. Quantbot Technologies LP acquired a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at $49,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

(Get Free Report

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

See Also

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.